Drugs, Money, and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices

Robin Feldman's book Drugs, Money, and Secret Handshakes reveals the pharmaceutical industry's web of shadowy deals, where higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines. This system of perverse incentives has delivered exorbitant drug prices and profits.

Format: Paperback / softback
Length: 200 pages
Publication date: 16 November 2023
Publisher: Cambridge University Press

In the distorted realm of prescription drug pricing, generic drugs often surpass their branded counterparts in cost, while older drugs are re-introduced at exorbitant prices, effectively excluding affordable options from the market. In her book, Drugs, Money, and Secret Handshakes, Robin Feldman delves into the shadowy underbelly of the pharmaceutical industry, unveiling a web of covert agreements that favor higher-priced drugs and steer patients towards the most expensive treatments. At the heart of this intricate network are the enigmatic middlemen who establish coverage levels for patients and engage in negotiations with drug companies. By showering these middlemen with lucrative payments (as well as to doctors and hospitals), drug companies ensure that inexpensive drugs never gain traction. This perverse system of incentives has resulted in exorbitant drug prices and staggering profits, cherished by many but despised by those who bear the financial burden.

The pharmaceutical industry operates in a complex and opaque manner, with various stakeholders involved in the pricing and distribution of drugs. One of the key players in this ecosystem are the middlemen, who act as intermediaries between drug companies and healthcare providers. These middlemen are responsible for negotiating coverage levels and prices for drugs, often receiving substantial payments in return. However, their role in the system has come under scrutiny, with some arguing that they contribute to higher drug prices by blocking the entry of affordable generic drugs into the market.

One of the ways in which middlemen influence drug pricing is through their negotiations with drug companies. Drug companies may offer discounts or other incentives to middlemen in exchange for their support in promoting and prescribing their drugs. These incentives can include marketing support, access to patient data, and favorable coverage decisions. However, the extent to which these incentives influence drug pricing is a matter of debate. Some argue that middlemen play a crucial role in ensuring that patients receive the appropriate treatment and that drug companies have access to the healthcare market. Others argue that they contribute to higher drug prices by favoring the most expensive drugs and blocking the entry of generic competitors.

Another factor that contributes to higher drug prices is the practice of evergreening. This refers to the practice of drug companies extending the patent life of their drugs, thereby preventing generic competitors from entering the market. By doing so, drug companies can maintain a monopoly on their products and charge higher prices. Evergreening can be seen as a way for drug companies to maximize their profits, but it can also have negative consequences for patients and healthcare systems. It can lead to a lack of competition in the drug market, which can result in higher prices and limited access to medications.

In addition to the practices of middlemen and evergreening, the pharmaceutical industry is also influenced by regulatory policies and pricing mechanisms. For example, the United States' healthcare system relies heavily on prescription drug coverage, which is provided through private insurance plans and government programs such as Medicare and Medicaid. Insurance companies may negotiate with drug companies for lower prices, which can impact the overall cost of drugs for patients. However, insurance companies may also place restrictions on coverage, such as requiring patients to try alternative treatments before they can receive a prescription for a more expensive drug.

Despite these challenges, there are efforts underway to address the issue of high drug prices. One approach is to promote the use of generic drugs, which are cheaper alternatives to brand-name drugs that have the same active ingredient. Generic drugs are typically manufactured by the same companies that produce brand-name drugs, but they do not incur the costs of marketing and advertising. As a result, they can be sold at a lower price to patients.

Another approach is to increase competition in the drug market. This can be achieved through policies that encourage the entry of new drug manufacturers and the development of new drugs. For example, the United States' Food and Drug Administration (FDA) has implemented policies that speed up the approval process for new drugs, making it easier for companies to bring new products to market.

In conclusion, the issue of high drug prices is complex and multifaceted. While there are various factors that contribute to these prices, including the practices of middlemen, evergreening, and regulatory policies, there are also efforts underway to address these issues. By promoting the use of generic drugs and increasing competition in the drug market, we can work towards ensuring that patients have access to affordable and effective medications.

ISBN-13: 9781009432948
Edition number: Revised ed